Which has better valuation & earnings, KZIA or SERA?

Novogen has higher earnings, but lower revenue than Sera Prognostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $30K 5,192.32 -$13.41M N/A N/A Sera Prognostics $70K 1,132.75 -$31.93M -$0.67 N/A

Does the media favor KZIA or SERA?

In the previous week, Novogen had 1 more articles in the media than Sera Prognostics. MarketBeat recorded 2 mentions for Novogen and 1 mentions for Sera Prognostics. Sera Prognostics' average media sentiment score of 0.59 beat Novogen's score of -0.16 indicating that Sera Prognostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novogen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Sera Prognostics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, KZIA or CRDF?

Novogen has higher earnings, but lower revenue than Cardiff Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $30K 5,192.32 -$13.41M N/A N/A Cardiff Oncology $508K 168.45 -$45.85M -$0.60 N/A

Does the media refer more to KZIA or CRDF?

In the previous week, Cardiff Oncology had 2 more articles in the media than Novogen. MarketBeat recorded 4 mentions for Cardiff Oncology and 2 mentions for Novogen. Cardiff Oncology's average media sentiment score of 0.71 beat Novogen's score of -0.16 indicating that Cardiff Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novogen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Cardiff Oncology 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, KZIA or YARW?

Novogen has higher earnings, but lower revenue than Yarrow Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $30K 5,192.32 -$13.41M N/A N/A Yarrow Bioscience $570K 137.25 -$26.48M -$14.64 N/A

Does the media prefer KZIA or YARW?

In the previous week, Yarrow Bioscience had 1 more articles in the media than Novogen. MarketBeat recorded 3 mentions for Yarrow Bioscience and 2 mentions for Novogen. Yarrow Bioscience's average media sentiment score of 0.90 beat Novogen's score of -0.16 indicating that Yarrow Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novogen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Yarrow Bioscience 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, GANX or KZIA?

Novogen has higher revenue and earnings than Gain Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gain Therapeutics N/A N/A -$20.16M -$0.50 N/A Novogen $30K 5,192.32 -$13.41M N/A N/A

Is GANX or KZIA more profitable?

Novogen's return on equity of 0.00% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -161.59% -118.36% Novogen N/A N/A N/A

Does the media refer more to GANX or KZIA?

In the previous week, Gain Therapeutics had 7 more articles in the media than Novogen. MarketBeat recorded 9 mentions for Gain Therapeutics and 2 mentions for Novogen. Gain Therapeutics' average media sentiment score of 0.00 beat Novogen's score of -0.16 indicating that Gain Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Novogen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend TELO or KZIA?

Novogen has a consensus price target of $27.33, suggesting a potential upside of 127.59%. Given Novogen's stronger consensus rating and higher possible upside, analysts plainly believe Novogen is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Novogen 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Which has stronger valuation and earnings, TELO or KZIA?

Telomir Pharmaceuticals has higher earnings, but lower revenue than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telomir Pharmaceuticals N/A N/A -$10.41M -$0.91 N/A Novogen $30K 5,192.32 -$13.41M N/A N/A

Is TELO or KZIA more profitable?

Novogen's return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Telomir Pharmaceuticals N/A -102.70% -90.75% Novogen N/A N/A N/A

Novogen (KZIA) Competitors

$12.01 -0.30 (-2.44%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$12.00 0.00 (-0.04%)

As of 09/8/2026 07:30 PM Eastern

Compare

KZIA vs. SERA, CRDF, YARW, GANX, and TELO

Should you buy Novogen stock or one of its competitors? Novogen's main competitors and comparable companies include Sera Prognostics (SERA), Cardiff Oncology (CRDF), Yarrow Bioscience (YARW), Gain Therapeutics (GANX), and Telomir Pharmaceuticals (TELO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Novogen compare to Sera Prognostics?

Novogen (NASDAQ:KZIA) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Novogen has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Novogen's return on equity of 0.00% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Sera Prognostics	-47,475.72%	-46.71%	-34.06%

Novogen has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market.

30.9% of Novogen shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 1.0% of Novogen shares are owned by company insiders. Comparatively, 11.3% of Sera Prognostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Novogen has higher earnings, but lower revenue than Sera Prognostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	5,192.32	-$13.41M	N/A	N/A
Sera Prognostics	$70K	1,132.75	-$31.93M	-$0.67	N/A

Novogen presently has a consensus price target of $27.33, suggesting a potential upside of 127.59%. Sera Prognostics has a consensus price target of $5.50, suggesting a potential upside of 173.63%. Given Sera Prognostics' higher possible upside, analysts clearly believe Sera Prognostics is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Novogen had 1 more articles in the media than Sera Prognostics. MarketBeat recorded 2 mentions for Novogen and 1 mentions for Sera Prognostics. Sera Prognostics' average media sentiment score of 0.59 beat Novogen's score of -0.16 indicating that Sera Prognostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novogen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Sera Prognostics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Novogen beats Sera Prognostics on 9 of the 15 factors compared between the two stocks.

How does Novogen compare to Cardiff Oncology?

Novogen (NASDAQ:KZIA) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Novogen has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market.

Novogen has a net margin of 0.00% compared to Cardiff Oncology's net margin of -7,885.43%. Novogen's return on equity of 0.00% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Cardiff Oncology	-7,885.43%	-103.10%	-75.52%

Novogen has higher earnings, but lower revenue than Cardiff Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	5,192.32	-$13.41M	N/A	N/A
Cardiff Oncology	$508K	168.45	-$45.85M	-$0.60	N/A

Novogen presently has a consensus price target of $27.33, indicating a potential upside of 127.59%. Cardiff Oncology has a consensus price target of $7.50, indicating a potential upside of 581.82%. Given Cardiff Oncology's higher possible upside, analysts plainly believe Cardiff Oncology is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Cardiff Oncology	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

30.9% of Novogen shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 1.0% of Novogen shares are owned by company insiders. Comparatively, 8.8% of Cardiff Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Cardiff Oncology had 2 more articles in the media than Novogen. MarketBeat recorded 4 mentions for Cardiff Oncology and 2 mentions for Novogen. Cardiff Oncology's average media sentiment score of 0.71 beat Novogen's score of -0.16 indicating that Cardiff Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novogen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Cardiff Oncology	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Novogen beats Cardiff Oncology on 9 of the 14 factors compared between the two stocks.

How does Novogen compare to Yarrow Bioscience?

Novogen (NASDAQ:KZIA) and Yarrow Bioscience (NASDAQ:YARW) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

30.9% of Novogen shares are held by institutional investors. Comparatively, 83.8% of Yarrow Bioscience shares are held by institutional investors. 1.0% of Novogen shares are held by company insiders. Comparatively, 3.0% of Yarrow Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Novogen has higher earnings, but lower revenue than Yarrow Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	5,192.32	-$13.41M	N/A	N/A
Yarrow Bioscience	$570K	137.25	-$26.48M	-$14.64	N/A

Novogen has a net margin of 0.00% compared to Yarrow Bioscience's net margin of -4,726.21%. Novogen's return on equity of 0.00% beat Yarrow Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%

Novogen presently has a consensus target price of $27.33, suggesting a potential upside of 127.59%. Yarrow Bioscience has a consensus target price of $58.00, suggesting a potential upside of 97.95%. Given Novogen's stronger consensus rating and higher possible upside, equities research analysts plainly believe Novogen is more favorable than Yarrow Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Yarrow Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Novogen has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market. Comparatively, Yarrow Bioscience has a beta of 2.01, suggesting that its share price is 101% more volatile than the broader market.

In the previous week, Yarrow Bioscience had 1 more articles in the media than Novogen. MarketBeat recorded 3 mentions for Yarrow Bioscience and 2 mentions for Novogen. Yarrow Bioscience's average media sentiment score of 0.90 beat Novogen's score of -0.16 indicating that Yarrow Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novogen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Yarrow Bioscience	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Novogen beats Yarrow Bioscience on 9 of the 14 factors compared between the two stocks.

How does Novogen compare to Gain Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Novogen (NASDAQ:KZIA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 30.9% of Novogen shares are held by institutional investors. 4.2% of Gain Therapeutics shares are held by company insiders. Comparatively, 1.0% of Novogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Gain Therapeutics had 7 more articles in the media than Novogen. MarketBeat recorded 9 mentions for Gain Therapeutics and 2 mentions for Novogen. Gain Therapeutics' average media sentiment score of 0.00 beat Novogen's score of -0.16 indicating that Gain Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gain Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Novogen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Novogen has higher revenue and earnings than Gain Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	N/A	N/A	-$20.16M	-$0.50	N/A
Novogen	$30K	5,192.32	-$13.41M	N/A	N/A

Gain Therapeutics currently has a consensus price target of $7.50, indicating a potential upside of 309.84%. Novogen has a consensus price target of $27.33, indicating a potential upside of 127.59%. Given Gain Therapeutics' higher possible upside, research analysts plainly believe Gain Therapeutics is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Novogen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Novogen's return on equity of 0.00% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-161.59%	-118.36%
Novogen	N/A	N/A	N/A

Gain Therapeutics has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market. Comparatively, Novogen has a beta of 2.14, indicating that its stock price is 114% more volatile than the broader market.

Summary

Novogen beats Gain Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Novogen compare to Telomir Pharmaceuticals?

Telomir Pharmaceuticals (NASDAQ:TELO) and Novogen (NASDAQ:KZIA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Telomir Pharmaceuticals has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market. Comparatively, Novogen has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market.

Novogen has a consensus price target of $27.33, suggesting a potential upside of 127.59%. Given Novogen's stronger consensus rating and higher possible upside, analysts plainly believe Novogen is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Novogen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Telomir Pharmaceuticals has higher earnings, but lower revenue than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.91	N/A
Novogen	$30K	5,192.32	-$13.41M	N/A	N/A

Novogen's return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-102.70%	-90.75%
Novogen	N/A	N/A	N/A

30.9% of Novogen shares are owned by institutional investors. 16.4% of Telomir Pharmaceuticals shares are owned by company insiders. Comparatively, 1.0% of Novogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Novogen had 2 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 2 mentions for Novogen and 0 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 0.00 beat Novogen's score of -0.16 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Telomir Pharmaceuticals	Neutral
Novogen	Neutral

Summary

Novogen beats Telomir Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

Get Novogen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KZIA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KZIA vs. The Competition

Export

Metric	Novogen	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$159.65M	$4.01B	$7.38B	$12.89B
Dividend Yield	N/A	3.60%	2.54%	9.14%
P/E Ratio	N/A	12.50	270.75	25.39
Price / Sales	5,192.32	1,491.38	660.64	98.81
Price / Cash	N/A	108.60	77.07	52.39
Price / Book	-2.25	15.97	10.88	6.40
Net Income	-$13.41M	-$22.81M	$3.48B	$358.18M
7 Day Performance	-4.76%	-0.88%	-0.98%	0.04%
1 Month Performance	-13.53%	4.81%	2.90%	-0.80%
1 Year Performance	49.19%	47.25%	22.18%	12.47%

Novogen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KZIA Novogen	4.1327 of 5 stars	$12.01 -2.4%	$27.33 +127.6%	+55.8%	$159.65M	$30K	N/A	12
SERA Sera Prognostics	2.5696 of 5 stars	$2.08 -1.9%	$5.50 +164.4%	-36.6%	$82.14M	$80K	N/A	120	Gap Down
CRDF Cardiff Oncology	2.617 of 5 stars	$1.03 -0.5%	$7.50 +631.7%	-50.7%	$80.52M	$508K	N/A	20
YARW Yarrow Bioscience	2.7233 of 5 stars	$29.93 -3.4%	$58.00 +93.8%	N/A	$79.81M	$570K	N/A	30
GANX Gain Therapeutics	2.555 of 5 stars	$1.79 +0.9%	$7.50 +319.9%	+4.6%	$78.33M	$50K	N/A	20	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KZIA) was last updated on 9/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novogen (KZIA) Competitors

KZIA vs. SERA, CRDF, YARW, GANX, and TELO

How does Novogen compare to Sera Prognostics?

Summary

How does Novogen compare to Cardiff Oncology?

Summary

How does Novogen compare to Yarrow Bioscience?

Summary

How does Novogen compare to Gain Therapeutics?

Summary

How does Novogen compare to Telomir Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZIA vs. The Competition

Novogen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novogen (KZIA) Competitors

KZIA vs. SERA, CRDF, YARW, GANX, and TELO

How does Novogen compare to Sera Prognostics?

Is KZIA or SERA more profitable?

Which has more volatility and risk, KZIA or SERA?

Do insiders and institutionals hold more shares of KZIA or SERA?

Which has better valuation & earnings, KZIA or SERA?

Do analysts recommend KZIA or SERA?

Does the media favor KZIA or SERA?

Summary

How does Novogen compare to Cardiff Oncology?

Which has more risk & volatility, KZIA or CRDF?

Is KZIA or CRDF more profitable?

Which has stronger earnings and valuation, KZIA or CRDF?

Do analysts recommend KZIA or CRDF?

Do institutionals & insiders have more ownership in KZIA or CRDF?

Does the media refer more to KZIA or CRDF?

Summary

How does Novogen compare to Yarrow Bioscience?

Do insiders and institutionals believe in KZIA or YARW?

Which has higher earnings and valuation, KZIA or YARW?

Is KZIA or YARW more profitable?

Do analysts recommend KZIA or YARW?

Which has more volatility and risk, KZIA or YARW?

Does the media prefer KZIA or YARW?

Summary

How does Novogen compare to Gain Therapeutics?

Do insiders and institutionals have more ownership in GANX or KZIA?

Does the media refer more to GANX or KZIA?

Which has preferable earnings and valuation, GANX or KZIA?

Do analysts prefer GANX or KZIA?

Is GANX or KZIA more profitable?

Which has more risk and volatility, GANX or KZIA?

Summary

How does Novogen compare to Telomir Pharmaceuticals?

Which has more volatility and risk, TELO or KZIA?

Do analysts recommend TELO or KZIA?

Which has stronger valuation and earnings, TELO or KZIA?

Is TELO or KZIA more profitable?

Do institutionals and insiders hold more shares of TELO or KZIA?

Does the media favor TELO or KZIA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZIA vs. The Competition

Novogen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools